Revenue from operations rose 6.4% to ₹720.3 crore from ₹676.8 crore a year earlier, supported by steady business growth.
EBITDA increased 2.7% year-on-year to ₹95.8 crore against ₹93.3 crore in Q4 FY25, while EBITDA margin remained broadly stable at 13.3% compared with 13.8% in the year-ago quarter.
Earlier, in Q3, the firm had reported a net profit of ₹40.5 crore, up 9.5% year-on-year from ₹37 crore.
Revenue from operations grew 8.1% year-on-year to ₹601.7 crore, compared with ₹556.6 crore in the same period last year.
EBITDA for the Q3 had declined 11.8% to ₹54.7 crore from ₹61.7 crore in the year-ago period. EBITDA margin stood at 9%, down from 11% in the corresponding quarter of the previous year.
Also Read: NCC Q4 net profit falls 19% as margins ease, revenue up 2%; declares ₹2.20 dividend
Shares of Aarti Drugs ended higher on Friday, with the stock closing at ₹367 on the National Stock Exchange of India, up ₹4.65 or 1.28% from the previous close.
Also Read: SEBI eases InvIT rules, allows SPVs to retain status post concession expiry
